The director of the Corinne Goldsmith Dickinson Center for MS at Mount Sinai School of Medicine spoke about the major issues in MS right now: being able to individually prognosticate, moving toward developing better therapies for a progressive disease, and repairing the damage to the nervous system.
What are the risk factors for serious intracranial injury? When can patients return to normal activity? Answers here.
The staff neurologist at the Mellen Center for MS at Cleveland Clinic spoke about the potential for the central vein sign to help address issues of misdiagnosis in multiple sclerosis
The vice president of US Medical Affairs in Neurology and Immunology at EMD Serono spoke to the next steps for the oral agent and its potential to get approved by the FDA in 2019.
The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the importance of long-term efficacy studies.
The director of the Mayo Clinic Alzheimer Disease Research Center and Mayo Clinic Study of Aging spoke about the current therapeutic landscape of Alzheimer disease, among other topics.
Neurology News Network for the week of March 9, 2019.
The staff neurologist at Cleveland Clinic's Mellen Center spoke about the importance of a comprehensive approach to managing patients with multiple sclerosis.
The chief of the Multiple Sclerosis Division at the University of Pennsylvania’s Perelman School of Medicine spoke about the need for more team-based care for patients with MS.
This young woman is otherwise healthy and doesn’t drink or abuse drugs. What’s in your differential diagnosis?
SEEG displayed better procedural morbidities and may have better outcomes than subdural grid electrodes, which study authors suggest should impact decision-making and lower the surgical candidacy barrier.
The Allergan product was granted Priority Review for upper limb spasticity and is expected to be decided on in the second quarter of 2019, while the lower limb indication will have its evaluation by the fourth quarter.
The vice president of US Medical Affairs in Neurology & Immunology at EMD Serono discussed the importance of having long-term and age-matched data on the use of the investigational oral agent in MS.
The professor of neurology at Harvard Medical School shared her methods for diagnosing pediatric MS and about the importance of managing the disease in a larger sense.
After showing success in older infants with SMA, risdiplam is now being evaluated in adults—something that’s never been done in a controlled trial of SMA.
The patient has a history of migraine. Is this another attack-or is something else going on?
The 23rd FDA commissioner’s resignation is effective in about a month; his successor has not yet been named.
If approved, galcanezumab would be the first preventive option approved for patients with episodic cluster headache in the United States.
The director of the probabilistic vision group and medical imaging lab at McGill University spoke about machine learning’s potential to help physicians predict MS disease progression, treatment effectiveness, and more.
The director of the Partners Multiple Sclerosis Center at Brigham and Women's Hospital spoke about the future of multiple sclerosis.
The spinal cord area has shown a strong link to MS disability and can help discriminate progressive and relapsing-remitting disease subtypes, which in turn could help inform individualized treatment plans.
The professor of neurology spoke about the challenges faced by MS specialists as their numbers dwindle and the number of patients surpasses 1 million in the United States.
A driver sees what appear to be squiggly lines in the right field of vision of her right eye.
The staff neurologist at the Mellen Center for MS at Cleveland Clinic discussed this challenge with misdiagnosis and how it impacts the clinicians who are treating these patients.
A pair of poster presentations regarding the use of cladribine in multiple sclerosis have shown that No Evidence of Disease Activity-3 status can be sustained up to 4 years, without any new safety signals appearing.
Data have suggested that neurologists treating MS have clearly and persistently deviated from the readily available evidence regarding DMT use, all while costs continue to rise and payers intensify efforts to control them.
A late-breaking poster has suggested that the use of disease-modifying therapy is safe in patients with MS over the age of 65, as well as that disability burden and relapse rates may be lower than believed.
The professor of medicine and community health sciences at the University of Manitoba spoke about the effects of comorbidity on diagnosis, outcomes, and treatment in multiple sclerosis.
The professor of neurology at Harvard Medical School provided some insight into her experience with treating pediatric patients with MS.
Despite being labeled as rare diseases, a number of neurologic conditions impact more patients than most would believe. The consultant with expertise in ophthalmology, gene therapy, and rare and orphan diseases, chimed in about how these diseases can often be overlooked.
